EP3375437A1 — Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
Assigned to Veroscience LLC · Expires 2018-09-19 · 8y expired
What this patent protects
The invention provides one or more agents that increase central dopaminergic neuronal activity selected from bromocriptine, lisuride, hydergine, dihydroergocriptine and/or dihydroergotoxine, plus a first-phase insulin secretagouge (FPIS), for use in treating prediabetes, Impaired…
USPTO Abstract
The invention provides one or more agents that increase central dopaminergic neuronal activity selected from bromocriptine, lisuride, hydergine, dihydroergocriptine and/or dihydroergotoxine, plus a first-phase insulin secretagouge (FPIS), for use in treating prediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance or Type 2 Diabetes, wherein the FPIS is glucagon like peptide-1 (GLP-1), insulin or a GLP-1 receptor agonist, wherein said agent is administered to a human to increase central dopaminergic activity primarily within 4 hours of waking in the morning.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.